检索范围:
排序: 展示方式:
A review of the safety and efficacy of current COVID-19 vaccines
《医学前沿(英文)》 2022年 第16卷 第1期 页码 39-55 doi: 10.1007/s11684-021-0893-y
关键词: COVID-19 SARS-CoV-2 vaccine safety efficacy effectiveness immunogenicity
Heterogeneous influence of individuals’ behavior on mask efficacy in gathering environments
《工程管理前沿(英文)》 页码 550-562 doi: 10.1007/s42524-022-0193-5
关键词: COVID-19 masks behavioral heterogeneity asymptomatic infection
Retrospective study of the efficacy and complication of thoracoabdominal incision for nephrectomy: a
Minggen YANG, Xiaokun ZHAO
《医学前沿(英文)》 2009年 第3卷 第2期 页码 191-196 doi: 10.1007/s11684-009-0026-5
Observation on therapeutic efficacy of ursodeoxycholic acid in Chinese patients with primary biliary
null
《医学前沿(英文)》 2013年 第7卷 第2期 页码 255-263 doi: 10.1007/s11684-012-0227-1
The efficacy of ursodeoxycholic acid (UDCA) on long-term outcome of primary biliary cirrhosis (PBC) has been less documented in Chinese cohort. We aimed to assess the therapeutic effect of UDCA on Chinese patients with PBC. In the present study, 67 patients with PBC were treated with UDCA (13–15 mg?kg-1?day-1) and followed up for 2 years to evaluate the changes of symptoms, laboratory values and histological features. As the results indicated, fatigue and pruritus were obviously improved by UDCA, particularly in patients with mild or moderate symptoms. The alkaline phosphatase and γ-glutamyl transpetidase levels significantly declined at year 2 comparing to baseline values, with the most profound effects achieved in patients at stage 2. The levels of alanine aminotransferase and aspartate aminotransferase significantly decreased whereas serum bilirubin and immunoglobulin M levels exhibited no significant change. Histological feature was stable in patients at stages 1–2 but still progressed in patients at stages 3–4. The biochemical response of patients at stage 2 was much better than that of patients at stages 3–4. These data suggest that, when treated in earlier stage, patients in long-term administration of UDCA can gain favorable results not only on symptoms and biochemical responses but also on histology. It is also indicated that later histological stage, bad biochemical response and severe symptom may be indicators of poor prognosis for UDCA therapy.
关键词: primary biliary cirrhosis ursodeoxycholic acid Chinese biochemical response therapeutic efficacy
《医学前沿(英文)》 2023年 第17卷 第3期 页码 493-502 doi: 10.1007/s11684-022-0946-x
关键词: ALK fusion next-generation sequencing fluorescence in situ hybridization immunohistochemistry variant allele frequency intratumoral heterogeneity targeted therapy
Protective efficacy of vaccination with NcMIC3 and NcMIC8 against
Taotao ZHANG, Xiao ZHANG, Qun LIU, Jianhai XU, Jing LIU
《农业科学与工程前沿(英文)》 2019年 第6卷 第2期 页码 188-196 doi: 10.15302/J-FASE-2019253
Microneme proteins (MICs) are important for Apicomplexan parasite invasion due to their adhesion to host cells. Several studies have indicated that MIC3 and MIC8 are important adhesion factors and potential vaccine candidates against neosporosis. In this study, we evaluated the protective efficacy of recombinant proteins and DNA vaccines of NcMIC3 and NcMIC8. BALB/c mice were immunized with rNcMIC3, rNcMIC8, pcDNA3.1-NcMIC3 and pcDNA3.1-NcMIC8 respectively, and challenged with tachyzoites. The immune responses were evaluated through cytokine, antibody measurements and the parasite burden in the mice brain tissues. Serological analysis showed that recombinant protein vaccines induced higher levels of immunoglobulin G (IgG) than other groups. The percentage of IgG1 and IgG2a in the recombinant protein groups was higher than the other groups, and with a predominance of IgG1 over IgG2a, suggesting that recombinant protein vaccines elicited a Th2-type immune response, while DNA vaccines mainly produce a Th1-type immune response. In addition, mice immunized with rNcMIC3 and rNcMIC8 a had lower parasite burden in brain tissue compared with the other groups. These results demonstrate that rNcMIC3 and rNcMIC8 could induce humoral and Th2-type immune response, leading to a considerable level of resistance against neosporosis.
PAN Jiangang, ZHOU Xing, CHEN Zhiguang, HAN Ruifa
《医学前沿(英文)》 2008年 第2卷 第3期 页码 259-263 doi: 10.1007/s11684-008-0049-3
Programming CAR T cells to enhance anti-tumor efficacy through remodeling of the immune system
Xiaohui Wang, Zhiqiang Wu, Wei Qiu, Ping Chen, Xiang Xu, Weidong Han
《医学前沿(英文)》 2020年 第14卷 第6期 页码 726-745 doi: 10.1007/s11684-020-0746-0
关键词: CAR T cells immunoregulatory molecules endogenous immune response solid malignancies
Effects and mechanisms of acupuncture on women related health
《医学前沿(英文)》 doi: 10.1007/s11684-023-1051-5
Yanli LIU, Rong LIU, Cheng ZHEN, Quanfang GUO, Liping WU, Zhaoxi DING, Yushun BI, Zhiyu LIU
《医学前沿(英文)》 2009年 第3卷 第1期 页码 91-95 doi: 10.1007/s11684-009-0011-z
关键词: Fuganling granula immunological liver injury bacille calmette guerin lipopolysaccharide mice
《医学前沿(英文)》 2022年 第16卷 第5期 页码 736-744 doi: 10.1007/s11684-021-0870-5
关键词: pneumoconiosis randomized controlled trials traditional Chinese medicine
《医学前沿(英文)》 2023年 第17卷 第2期 页码 275-289 doi: 10.1007/s11684-022-0945-y
关键词: epidermal growth factor receptor ErbB receptors HM781-36B nasopharyngeal carcinoma molecular targeted therapy cisplatin
Neoadjuvant radiohormonal therapy for oligo-metastatic prostate cancer: safety and efficacy outcomes
《医学前沿(英文)》 2023年 第17卷 第2期 页码 231-239 doi: 10.1007/s11684-022-0939-9
关键词: neoadjuvant radiotherapy oligometastatic prostate cancer radical prostatectomy
Huicong KANG, Xiaoyan LIU, Hu QI, Feng XU, Xiang LI, Yuan WANG, Zhiguang LIU, Suiqiang ZHU
《医学前沿(英文)》 2009年 第3卷 第2期 页码 181-186 doi: 10.1007/s11684-009-0025-6
提升疗效的修饰型治疗性抗体国内外研究进展 Review
戴济民, 张雪芹, 戴竞耀, 杨向民, 陈志南
《工程(英文)》 2021年 第7卷 第11期 页码 1529-1540 doi: 10.1016/j.eng.2020.06.030
生物治疗药物市场的繁荣反映了治疗性抗体药物用于治疗癌症、炎性疾病和难治性感染的可行性和有效性。随着抗体药物临床试验和转化研究中出现的结合效率不高、效应功能降低和不良反应频发等问题的解决,治疗性抗体的修饰在抗体药物的研发进程中得到了前所未有的蓬勃发展。为了提升抗体的结合活性、循环中的半衰期、靶细胞的有效性,并最终实现改善抗体药物的疗效,抗体可主要通过以下途径修饰:①糖基化修饰;②抗体恒定区(Fc)改造;③抗体亚类重构;④构建抗体-药物偶联物(ADC);⑤基于单链可变区片段(scFv)的嵌合抗原受体T细胞(CAR-T);⑥双特异性抗体(bsAb)。过去几十年来全球在修饰型治疗性抗体的领域取得了许多成就,中国作为对于生物治疗药物需求巨大并且拥有巨大研发潜力的国家在该领域亦发挥了积极作用。本文概括了修饰型治疗性抗体在当前国际研究中取得的进展,并在单独的章节中重点介绍了中国在该领域取得的成果。
标题 作者 时间 类型 操作
Retrospective study of the efficacy and complication of thoracoabdominal incision for nephrectomy: a
Minggen YANG, Xiaokun ZHAO
期刊论文
Observation on therapeutic efficacy of ursodeoxycholic acid in Chinese patients with primary biliary
null
期刊论文
Potential unreliability of ALK variant allele frequency in the efficacy prediction of targeted therapy
期刊论文
Protective efficacy of vaccination with NcMIC3 and NcMIC8 against
Taotao ZHANG, Xiao ZHANG, Qun LIU, Jianhai XU, Jing LIU
期刊论文
A meta-analysis of randomized trials of maintenance bacillus Calmette-Guerin instillation efficacy against
PAN Jiangang, ZHOU Xing, CHEN Zhiguang, HAN Ruifa
期刊论文
Programming CAR T cells to enhance anti-tumor efficacy through remodeling of the immune system
Xiaohui Wang, Zhiqiang Wu, Wei Qiu, Ping Chen, Xiang Xu, Weidong Han
期刊论文
Experimental study on the efficacy of Fuganling granula on protecting against immunological hepatic injury
Yanli LIU, Rong LIU, Cheng ZHEN, Quanfang GUO, Liping WU, Zhaoxi DING, Yushun BI, Zhiyu LIU
期刊论文
Clinical efficacy of comprehensive therapy based on traditional Chinese medicine patterns on patients
期刊论文
A small-molecule pan-HER inhibitor alone or in combination with cisplatin exerts efficacy against nasopharyngeal
期刊论文
Neoadjuvant radiohormonal therapy for oligo-metastatic prostate cancer: safety and efficacy outcomes
期刊论文
Prospective research on the efficacy and safety of oxcarbazepine as monotherapy and add-on therapy for
Huicong KANG, Xiaoyan LIU, Hu QI, Feng XU, Xiang LI, Yuan WANG, Zhiguang LIU, Suiqiang ZHU
期刊论文